IRWD 241220 10.00C (IRWD241220C10000) Stock Options, News & Quotes

US OptionsDetailed Quotes

IRWD241220C10000

Watchlist

0.10
0.000.00%

15min DelayTrading Oct 9 10:02 ET

0.00High0.00Low

Intraday

5D
Daily

News

US Manufacturing Index Rises To 43, Highest Since 2020
Business TodayNov 16 02:13 ET
Ironwood Pharmaceuticals to Participate in the Jefferies London Healthcare Conference
BusinesswireNov 13 16:01 ET
Shareholders Can't Ignore US$5.7m Of Sales By Ironwood Pharmaceuticals Insiders
Simply Wall StNov 9 07:13 ET
Ironwood Pharmaceuticals, Inc. (IRWD) Q3 2024 Earnings Call Transcript
Earnings Call TranscriptsNov 7 22:34 ET
Ironwood Pharmaceuticals | 10-Q: Q3 2024 Earnings Report
SECNov 7 17:29 ET · Announcements
JMP Securities Maintains Ironwood Pharmaceuticals(IRWD.US) With Buy Rating, Maintains Target Price $23
Moomoo NewsNov 7 13:33 ET · Ratings

Comments

Meltyy

May 12 21:23

🎯 Ph 3 readouts in Q2 2024...

$United Therapeutics (UTHR.US)$ Phase 3
$Ironwood Pharmaceuticals (IRWD.US)$ Phase 3
$Liquidia (LQDA.US)$ Phase 3
$United Therapeutics (UTHR.US)$ Phase 3
$MorphoSys (MOR.US)$ Phase 3
$Immunocore (IMCR.US)$ Phase 3
$Crinetics (CRNX.US)$ Phase 3
$UroGen Pharma Ltd (URGN.US)$ Phase 3
$AstraZeneca (AZN.US)$ Phase 3
$AstraZeneca (AZN.US)$ Phase 3
$AstraZeneca (AZN.US)$ Phase 3
$AstraZeneca (AZN.US)$ Phase 3
$Capricor Therapeutics (CAPR.US)$ Phase 3
$Annexon (ANNX.US)$ Phase 3
$Lipocine (LPCN.US)$ Phase 3...

Luzi Ann Santos

Feb 29 10:54

Columns Ironwood Pharma Shares Tank 40% as Drug Trial Misses Secondary Goal

$Ironwood Pharmaceuticals (IRWD.US)$ shares sank almost 40% after the drugmaker said its global phase III trial of Apraglutide, a treatment for short bowel syndrome, missed two of its four secondary goals.
That muddies the prospects for the company that's seeking to expand its product pipeline beyond Linzess.
Ironwood, which has been operating at a loss, sourced almost ll of its $117.6 million revenue in 2023 from its collaborati...

Meltyy

Feb 21 22:05

Biotech Stock Catalyst Watchlist

🎯 Ph 3 readouts in Q1 2024...
$Pfizer (PFE.US)$ Phase 3
$Palatin Technologies (PTN.US)$ Phase 3
$Annovis Bio (ANVS.US)$ Phase 3
$BioCardia (BCDA.US)$ Phase 3
$Atea Pharmaceuticals (AVIR.US)$ Phase 3
$Ironwood Pharmaceuticals (IRWD.US)$ Phase 3
$Alnylam Pharmaceuticals (ALNY.US)$ Phase 3
$Axsome Therapeutics (AXSM.US)$ Phase 3
$ $Novocure (NVCR.US)$ Phase 3
$ROCHE HOLDING AG (RHHBY.US)$ Phase 3
$FibroGen (FGEN.US)$ Phase 3
$ACADIA Pharmaceuticals (ACAD.US)$ Phase 3
$Sellas Life Sciences (SLS.US)$...

Moomoo AI

Feb 18 08:16

Thomas McCourt's recent sale at the current share price of US$14.58 raises caution. More selling than buying by insiders over the past year and low insider ownership could concern potential investors.

Ironwood Pharmaceuticals CEO & Director Thomas McCourt Sells 39% Of Holding

Meltyy

Jan 31 14:38

Ph 3 readouts in Q1 2024...

$Pfizer (PFE.US)$ Phase 3
$Regenxbio (RGNX.US)$ Phase 3
$Annovis Bio (ANVS.US)$ Phase 3
$Atea Pharmaceuticals (AVIR.US)$ Phase 3
$Ironwood Pharmaceuticals (IRWD.US)$ Phase 3
$Alnylam Pharmaceuticals (ALNY.US)$ Phase 3
$Vertex Pharmaceuticals (VRTX.US)$ Phase 3
$KalVista Pharmaceuticals (KALV.US)$ Phase 3
$Axsome Therapeutics (AXSM.US)$ Phase 3
$Novocure (NVCR.US)$ Phase 3
$ROCHE HOLDING AG (RHHBY.US)$ Phase 3
$FibroGen (FGEN.US)$ Phase 3
$Applied Therapeutics (APLT.US)$ Phase 3
$ACADIA Pharmaceuticals (ACAD.US)$ Phase 3...